Created by: Hellenbrecht (ELIC) , last changed: 2008/04/02
The “Clinical Trials Platform” integrates European expertise, explores and validates new therapeutic interventions and incorporates translational research to rapid applications in public health.
The integration of the leading leukemia trial groups across Europe will enable the conduction of cooperative trials even on rare subentities of the leukemias and related syndromes. By the use of standardized data sets and common guidelines for the conduction of phase I/II trials, trial quality will be of high standards and the outcomes will be comparable across Europe. Through the transparency and visibility of the clinical trials platform and the availability of large patient numbers, the transition time from drug discovery to its application at the bedside will be significantly shortened. The network will encourage participation in trials and acceptance of clinical research.
|Project 6: Acute Lymphoblastic Leukemia (ALL)
Major aims are the cooperation in Europe on basic and (pre-) clinical research, as well as diagnostic methods and spread of ...
|Project 5: Acute myeloplastic leukemia (AML)
This project aims at integrating the acquired cross disciplinary input from high quality AML trials as well as from new ...
|Project 4: Chronic myeloid leukemia (CML)
The main objective of this project is to integrate the leading European national trial groups in CML to form a cooperative ...
|Project 7: Chronic Lymphocytic Leukemia (CLL)
Project 7 aims to integrate all major European CLL study groups in a European CLL trial platform to promote the performance of ...
|Project 9: Chronic myeloproliferative diseases (CMPD)
Project 9 aims to integrate all major European CMPD study groups in a European Research Network to promote the standardization ...
|Project 8: Myelodysplastic syndromes (MDS)
This project aims at integrating the acquired cross disciplinary input from high quality, standardized MDS trials as well as ...